Surrozen Inc Dossier - Source-backed chat

Surrozen Inc

SRZNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.71

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $30.00Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $352.6M

Shares Outstanding 11.8M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Surrozen Inc. has strategically pivoted to focus exclusively on its high-potential ophthalmology pipeline, leveraging its proprietary Wnt signaling platform. Following the discontinuation of its clinical-stage liver asset SZN-043 in early 2025, the company is fully dedicated to advancing multi-specific antibody candidates for sight-threatening retinal diseases. The lead candidate, SZN-8141, is a bi-functional antibody combining Frizzled-4 (Fzd4) Wnt agonism with VEGF inhibition, designed to offer superior retinal drying, potential reperfusion of non-perfused areas, and longer dosing intervals compared to standard-of-care anti-VEGF monotherapies. Backed by a strong cash position of $106.9 million as of Q1 2026 and a structured $175 million private placement—where a $105 million second tranche is triggered upon FDA clearance of the SZN-8141 IND in H2 2026—Surrozen is well-capitalized to transition back into a clinical-stage company with significant near-term catalysts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$40.00

Mean target$42.50

High · most bullish analyst$44.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$36.0015%

The SZN-8141 IND submission is delayed or faces an FDA clinical hold, delaying the activation of the critical $105 million funding tranche and accelerating cash burn. Merck's Restoret clinical trials fail to show efficacy, severely damaging investor confidence in the Wnt pathway's therapeutic viability for retinal diseases. Preclinical efficacy fails to translate to human subjects in early Phase 1 trials.

Base CaseCentral scenario

$42.5050%

Matches the consensus mean

Surrozen submits and obtains FDA clearance for the SZN-8141 IND in the second half of 2026, securing the $105 million tranche of funding and initiating Phase 1 clinical trials. The company progresses SZN-8143 (tri-specific Wnt/VEGF/IL-6) toward IND-enabling studies. Early clinical development proceeds on schedule, and the cash runway is extended into late 2027/2028.

Bull CaseUpside scenario

$44.0035%

SZN-8141 successfully receives FDA IND clearance in H2 2026, triggering the $105 million second tranche of private placement funding. Preclinical synergy translates into human trials, demonstrating superior efficacy in retinal drying and unique reperfusion of non-perfused retinal areas. Merck's Restoret reports positive Phase 2b/3 data in late 2026, validating the Wnt pathway mechanism and driving a sector-wide re-rating of Wnt-focused biotechs. Boehringer Ingelheim advances SZN-413, triggering further development milestones.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Multi-Pathway Approach: SZN-8141 combines Wnt pathway repair mechanisms with VEGF inhibition in a single molecule, showing preclinical superiority over monotherapies.
Strong Capital Position: Well-capitalized with $106.9 million in cash as of March 31, 2026, plus a committed $105 million tranche contingent on SZN-8141 IND clearance.
Validated Platform Partnerships: Collaboration with Boehringer Ingelheim for SZN-413 provides external validation and up to $586.5 million in potential future milestones.

Key Investment Risks

Pre-Commercial and Pre-Clinical Stage: Following the discontinuation of SZN-043, the company has no active clinical-stage assets, exposing it to high development and regulatory risks.
Binary Funding Catalyst: The receipt of the $105 million second tranche of private placement funding is entirely contingent on FDA clearance of the SZN-8141 IND.
Intense Competition: The retinal disease space is highly competitive, dominated by established anti-VEGF blockbusters (e.g., Eylea, Vabysmo) and fast-moving Wnt competitors like Merck's Restoret.

Thesis Invalidation Triggers

FDA refusal or prolonged clinical hold on the SZN-8141 IND application in H2 2026.
Failure of Merck's Restoret in Phase 2b/3 trials, which would undermine the clinical thesis of Wnt signaling in retinal vascular diseases.
Termination of the SZN-413 partnership by Boehringer Ingelheim.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.